Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
894 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | recruiting | Phase 3 | 170 | AbbVieINDUSTRY | 9 | Apr 9, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER |
| 1 |
| Apr 9, 2026 |
| clinicaltrials |
| NCT07291973 | Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.(AURORA) | recruiting | N/A | 43 | Endowave Ltd.INDUSTRY | 2 | Apr 9, 2026 | clinicaltrials |
| NCT05570422 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 | recruiting | Phase 1 | 70 | Kortuc, Inc.INDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT06522737 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype(TERZO) | recruiting | Phase 3 | 124 | SecuraBioINDUSTRY | 10 | Apr 6, 2026 | clinicaltrials |
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06408441 | The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)(EHE) | recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 10 | Apr 3, 2026 | clinicaltrials |
| NCT06850623 | Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer(ENACT) | recruiting | Phase 2 | 25 | EXACT Therapeutics ASINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT05695222 | Cutaneous Squamous Cell Carcinoma Staging Study | recruiting | — | 1,500 | Queen Mary University of LondonOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT04109079 | Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy(ATNEC) | recruiting | N/A | 1,900 | University Hospitals of Derby and Burton NHS Foundation TrustOTHER | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05655078 | Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma(HIT-Meso) | recruiting | N/A | 148 | University College, LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06280781 | Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)(IP9-ATLAS) | recruiting | N/A | 1,263 | Imperial College LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06672926 | NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway(NEWPROMRI) | recruiting | — | 1,600 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07498829 | Population Based Germline Testing for Early Detection and Prevention of Cancer(PROTECT-C) | recruiting | N/A | 6,000 | Queen Mary University of LondonOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06695494 | Enabling Genomic Testing in Cancer of Unknown Primary(EGGCUP) | recruiting | — | 100 | The Christie NHS Foundation TrustOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT06638541 | Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions(DESTINATION 2) | recruiting | N/A | 54 | Royal Marsden NHS Foundation TrustOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT05539638 | The Role of Circulating Tumour DNA in Head and Neck Cancer | recruiting | — | 250 | University of EdinburghOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07201038 | Ultrafast Whole Genome Sequencing for Childhood Cancer(UF-WGS) | recruiting | — | 50 | University of CambridgeOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07084571 | Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution(FORTITUDE) | recruiting | — | 200 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06617897 | Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery | recruiting | Phase 3 | 90 | CSL BehringINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07219277 | Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening | recruiting | — | 2,000 | Syantra Inc.INDUSTRY | 3 | Mar 11, 2026 | clinicaltrials |
| NCT03141021 | Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | recruiting | — | 1,050 | Washington University School of MedicineOTHER | 5 | Mar 9, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT05604963 | Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers(HoT) | recruiting | N/A | 456 | University College, LondonOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07046559 | A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants | recruiting | Phase 1 | 104 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06309745 | THERApy De-escalation for TESTicular Cancer(THERATEST) | recruiting | — | 30 | Queen Mary University of LondonOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT07064122 | A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | recruiting | Phase 1 | 72 | AstraZenecaINDUSTRY | 7 | Mar 2, 2026 | clinicaltrials |
| NCT02790983 | Primary Tumor Research and Outcomes Network(PTRON) | recruiting | — | 1,350 | AO Innovation Translation CenterOTHER | 9 | Feb 25, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT03463954 | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | recruiting | N/A | 122 | Novian Health Inc.INDUSTRY | 5 | Feb 19, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis(ADAPT Jr) | recruiting | Phase 2 / Phase 3 | 12 | argenxINDUSTRY | 12 | Feb 18, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT04671940 | Exploratory Study of Clonal Evolution in Cancer for Patients Undergoing Transoral Robotic Surgery for Radiation Exposed Residual/reCurrent Tumours of the Upper Aerodigestive Tract(RECUT Plus) | recruiting | — | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials